May 1, 2020

How Precision is responding to COVID-19

Protecting our employees, continuing the important work of our clients Precision for Medicine, part of Precision Medicine Group’s global team of pharmaceutical and life science experts, is diligently monitoring and complying with the latest state, national, and international regulatory guidelines surrounding the COVID-19 pandemic commonly known as the “coronavirus.” While […]
Do you like it?
Read more
April 21, 2020

Precision for Medicine Partners with Karyopharm Therapeutics to Initiate New Global Clinical Trial to Treat Patients with COVID-19

PRECISION FOR MEDICINE PARTNERS WITH KARYOPHARM THERAPEUTICS TO INITIATE NEW GLOBAL CLINICAL TRIAL TO TREAT PATIENTS WITH COVID-19 — First Study of an XPO1 Inhibitor to Treat Patients with Severe Viral Infections — Precision for Medicine Responsible for Clinical Trial Management in Europe BUDAPEST, April 22, 2020 – Precision for […]
Do you like it?
Read more
April 2, 2020

EVICTION Trial to Evaluate Anti-cancer Drug ICT01 Launches

First-in-human, international, multi-center trial to test Butyrophylin 3A-targeted antibody in advanced solid and hematologic tumors – Precision provides global central lab support and US site management Marseille, France, March 26, 2020 – ImCheck Therapeutics announced today that it has dosed the first patient in a Phase I/IIa clinical trial evaluating […]
Do you like it?
Read more
Prev page
12345678910111213141516171819202122232425262728293031323334353637383940414243444546
Next page

Precision for Medicine is part of the Precision Medicine Group, an integrated team of experts that extends Precision for Medicine’s therapeutic development capabilities beyond approval and into launch strategies, marketing communication, and payer insights. As one company, the Precision Medicine Group helps pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.

Visit the website